Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study (CTS)

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Transplantation, Organ

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01476943

IM103-077

Details and patient eligibility

About

The primary purpose is to describe the pattern of Belatacept use at the time of transplant and up to three years post-transplantation for all Belatacept treated patients.

Full description

Time Perspective: Prospective design, Retrospective data collection and analysis

Enrollment: 72,392 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients who received solid organ transplantation during study period in one of the transplant centers involved in CTS

Trial design

72,392 participants in 2 patient groups

Patient treated with Belatacept at the time of transplantation

Description:

Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation

Patient treated with CNI at the time of transplantation

Description:

Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation